Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2004 Nov;80(949):670–674. doi: 10.1136/pgmj.2003.016030

Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes

A Bhansali 1, S Bhadada 1, A Sharma 1, V Suresh 1, A Gupta 1, P Singh 1, A Chakarbarti 1, R Dash 1
PMCID: PMC1743145  PMID: 15537854

Abstract

Aim: To report presentation and outcome of rhino-orbital-cerebral mucormycosis (ROCM) exclusively in patients with diabetes mellitus.

Methods: Retrospective, non-comparative, interventional analysis of the medical records of 35 patients with ROCM among 22 316 patients with diabetes seen over the last 12 years.

Results: A cohort of 23 men and 12 women with a mean (SD) age of 47.3 (14.4) years (range 18–70 years) was studied. Five patients had type 1 diabetes mellitus, 29 had type 2 diabetes mellitus, and one had secondary diabetes. Nine patients had ROCM as the first clinical manifestation of diabetes. The mean (SD) blood glucose at presentation was 20.6 (8.3) mmol/l (range 10.0 to 53.3 mmol/l) and 17 patients had ketosis/ketoacidosis. Ophthalmic symptoms and signs were pronounced: external ophthalmoplegia (89%), proptosis (83%), visual loss (80%), chemosis (74%), and eye lid gangrene (14%). Non-ophthalmic manifestations included sinusitis (100%), nasal discharge/ulceration (74%), infranuclear VI nerve palsy (46%), palatal necrosis (29%), cerebral lobe involvement (20%), and hemiparesis (17%). Computed tomography/magnetic resonance imaging showed involvement of paranasal sinuses in all patients with ethmoid (86%) and maxillary (80%) sinuses being most frequently involved. Orbital involvement was observed in 80% of patients with cavernous sinus thrombosis in 11%, and internal carotid occlusion and hydrocephalus in 3% each. All were treated with amphotericin B (3–3.5 g) and 26 (74%) patients underwent appropriate surgery. Twenty one patients (68%) survived with a mean (SD) follow up of 39.6 (34.1) months (range 10 months to 11 years). Factors related to poor survival included delay in diagnosis and treatment (p<0.05), facial and/or eye lid gangrene (p<0.05), hemiplegia (p<0.05), cerebral invasion by mucorales (p<0.05), and treatment with amphotericin B alone (p<0.05).

Conclusions: In patients with diabetes and ROCM, ROCM was the presenting manifestation in one fourth of the patients. Ophthalmic and extensive cerebral involvement predominated in the clinical picture. Delay in treatment due to late presentation and associated complications were major determinants of the survival outcome in these patients.

Full Text

The Full Text of this article is available as a PDF (226.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell S., Mahoney L. Mucormycosis: a case study. Crit Care Nurse. 2000 Feb;20(1):18–23. [PubMed] [Google Scholar]
  2. Bhansali A., Sharma A., Kashyap A., Gupta A., Dash R. J. Mucor endophthalmitis. Acta Ophthalmol Scand. 2001 Feb;79(1):88–90. doi: 10.1034/j.1600-0420.2001.079001088.x. [DOI] [PubMed] [Google Scholar]
  3. Blitzer A., Lawson W., Meyers B. R., Biller H. F. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope. 1980 Apr;90(4):635–648. doi: 10.1288/00005537-198004000-00010. [DOI] [PubMed] [Google Scholar]
  4. Cohen S. G., Greenberg M. S. Rhinomaxillary mucormycosis in a kidney transplant patient. Oral Surg Oral Med Oral Pathol. 1980 Jul;50(1):33–38. doi: 10.1016/0030-4220(80)90328-x. [DOI] [PubMed] [Google Scholar]
  5. Ferry A. P., Abedi S. Diagnosis and management of rhino-orbitocerebral mucormycosis (phycomycosis). A report of 16 personally observed cases. Ophthalmology. 1983 Sep;90(9):1096–1104. doi: 10.1016/s0161-6420(83)80052-9. [DOI] [PubMed] [Google Scholar]
  6. Humphry R. C., Wright G., Rich W. J., Simpson R. Acute proptosis and blindness in a patient with orbital phycomycosis. J R Soc Med. 1989 May;82(5):304–305. doi: 10.1177/014107688908200523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lacy P. E., Lacy E. T., Finke E. H., Yasunami Y. An improved method for the isolation of islets from the beef pancreas. Diabetes. 1982 Aug;31 (Suppl 4):109–111. doi: 10.2337/diab.31.4.s109. [DOI] [PubMed] [Google Scholar]
  8. Maniglia A. J., Mintz D. H., Novak S. Cephalic phycomycosis: a report of eight cases. Laryngoscope. 1982 Jul;92(7 Pt 1):755–760. doi: 10.1288/00005537-198207000-00008. [DOI] [PubMed] [Google Scholar]
  9. Marchevsky A. M., Bottone E. J., Geller S. A., Giger D. K. The changing spectrum of disease, etiology, and diagnosis of mucormycosis. Hum Pathol. 1980 Sep;11(5):457–464. doi: 10.1016/s0046-8177(80)80054-2. [DOI] [PubMed] [Google Scholar]
  10. Ochi J. W., Harris J. P., Feldman J. I., Press G. A. Rhinocerebral mucormycosis: results of aggressive surgical debridement and amphotericin B. Laryngoscope. 1988 Dec;98(12):1339–1342. doi: 10.1288/00005537-198812000-00011. [DOI] [PubMed] [Google Scholar]
  11. Parfrey N. A. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine (Baltimore) 1986 Mar;65(2):113–123. doi: 10.1097/00005792-198603000-00004. [DOI] [PubMed] [Google Scholar]
  12. Pillsbury H. C., Fischer N. D. Rhinocerebral mucormycosis. Arch Otolaryngol. 1977 Oct;103(10):600–604. doi: 10.1001/archotol.1977.00780270068011. [DOI] [PubMed] [Google Scholar]
  13. Smith J. L., Stevens D. A. Survival in cerebro-rhino-orbital zygomycosis and cavernous sinus thrombosis with combined therapy. South Med J. 1986 Apr;79(4):501–504. doi: 10.1097/00007611-198604000-00028. [DOI] [PubMed] [Google Scholar]
  14. Yohai R. A., Bullock J. D., Aziz A. A., Markert R. J. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol. 1994 Jul-Aug;39(1):3–22. doi: 10.1016/s0039-6257(05)80041-4. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES